How can we reduce complications associated with thrombolysis for prosthetic valve thrombosis? (Authors Reply To the Editor,)

Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial. Özkan

In our article published in the Anatolia Journal of Cardiology in late 2016 entitled “A hypertrophic and dilated cardiomyopathic sudden cardiac death case; de novo mutations TTN

In agreement with the authors, I suggest using ABO blood types as a new factor in the stratification of risk of thrombosis in patients with prosthetic heart valve.. Fidel

Conclusion: Our data demonstrate that patients with non-0 compared with 0 blood groups have higher incidence of prosthetic valve thrombosis and central nervous system embolism

A 14x9 mm sized non-obstructive, echoluscent-structured, mobile mass was detected which was attached to the annulus pos- terior to the prosthetic mitral valve and mild

We have read with great interest the case report entitled ‘A case of unusual looking prosthetic mitral valve thrombosis treated with low dose slow infusion tPA’ published in May

2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/ American Heart Association Task Force on

Management of acute ischemic stroke occurred during thrombolytic treatment of a patient with prosthetic mitral valve thrombosis: continuing thrombolysis on top of